Indaptus Therapeutics (INDP) EBIT (2020 - 2026)

Indaptus Therapeutics' EBIT history runs 7 years deep, the most recent figure standing at -$2.2 million for Q1 2026.

• In Q1 2026, EBIT rose 52.77% year-over-year to -$2.2 million; the TTM figure through Mar 2026 stood at -$17.4 million (down 8.91% YoY), while the FY2025 annual figure was -$19.8 million, down 29.08% from the prior year.
• EBIT for Q1 2026 stood at -$2.2 million, up from -$8.2 million in the prior quarter.
• The five-year high for EBIT was -$2.2 million in Q1 2026, with the low at -$8.2 million in Q4 2025.
• The 5-year median for EBIT is -$4.1 million (2022), against an average of -$4.0 million.
• The sharpest annual moves came in 2022 and 2026: EBIT plunged 631.92% in 2022, then jumped 52.77% in 2026.
• Indaptus Therapeutics' EBIT stood at -$4.1 million in 2022, then dropped by 2.27% to -$4.2 million in 2023, then grew by 0.19% to -$4.2 million in 2024, then slumped by 95.51% to -$8.2 million in 2025, then jumped by 73.52% to -$2.2 million in 2026.
• Business Quant data shows INDP's EBIT at -$2.2 million in Q1 2026, -$8.2 million in Q4 2025, and -$2.6 million in Q3 2025.